Skip to main content
SpringerLink
Log in
Book cover

Perinatal Psychopharmacology pp 181–190Cite as

Mood Stabilizers in Pregnancy

  • Chapter
  • First Online:

Abstract

The increased risk of onset or recurrence of bipolar disorders during the perinatal period raises the crucial question of management of mood stabilizers. Women and their partners have to be informed and helped to be able to give an informed consent for the choice that they make. For clinicians, the prescription of mood stabilizers, as that of any psychotropic drug during pregnancy, is challenging, and they have to be able to weigh the risk of a maternal relapse vs. the risk of antenatal exposure to the drug, that is, should treatment be interrupted or modified against the teratogenic or fetotoxic risk of antenatal exposure to the drug.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Viguera AC, Tondo L, Koukopoulos AE, Reginaldi D, Lepri B, Baldessarini RJ. Episodes of mood disorders in 2252 pregnancies and postpartum periods. Am J Psychiatry. 2011;168:1179–85.

    Article  Google Scholar 

  2. Van der Lugt NM, Van de Maat JS, Van Kamp IL, Knoppert-van der Klein EA, Hovens JG, Walther FJ. Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies. Early Hum Dev. 2012;88:375–8.

    Article  Google Scholar 

  3. Jones I, Craddock N. Bipolar disorder and childbirth: the importance of recognising risk. Br J Psychiatry. 2005;186:453–4.

    Article  Google Scholar 

  4. Bodén R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012;345:e7085.

    Article  Google Scholar 

  5. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry. 2002;63(Suppl 4):42–55.

    CAS  PubMed  Google Scholar 

  6. Clark CT, Klein AM, Perel JM, Helsel J, Wisner KL. Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry. 2013;170:1240–7.

    Article  Google Scholar 

  7. Gaffield ME, Culwell KR, Lee CR. The use of hormonal contraception among women taking anticonvulsant therapy. Contraception. 2011;83:16–29.

    Article  CAS  Google Scholar 

  8. Zhang L, Li H, Li S, Zou X. Reproductive and metabolic abnormalities in women taking valproate for bipolar disorder: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2016;202:26–31.

    Article  Google Scholar 

  9. Sutter-Dallay AL, Bales M, Pambrun E, Glangeaud-Freudenthal NM, Wisner KL, Verdoux H. Impact of prenatal exposure to psychotropic drugs on neonatal outcome in infants of mothers with serious psychiatric illnesses. J Clin Psychiatry. 2015;76:967–73.

    Article  Google Scholar 

  10. Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry. 2005;162:2162–70.

    Article  Google Scholar 

  11. Giles JJ, Bannigan JG. Teratogenic and developmental effects of lithium. Curr Pharm Des. 2006;12:1531–41.

    Article  CAS  Google Scholar 

  12. Schou M, Goldfield MD, Weinstein MR, Villieneuve A. Lithium and pregnancy. I. Report from the Register of Lithium Babies. BMJ. 1973;2:135–6.

    Article  CAS  Google Scholar 

  13. Weinstein MR, Goldfield M. Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry. 1975;132:529–31.

    Article  CAS  Google Scholar 

  14. Kozma C. Neonatal toxicity and transient neurodevelopmental deficits following prenatal exposure to lithium: another clinical report and a review of the literature. Am J Med Genet A. 2005;132A(4):441–4.

    Article  Google Scholar 

  15. Nora JJ, Nora AH, Toews WH. Lithium, Ebstein’s anomaly, and other congenital heart defects. Lancet. 1974;2(7880):594–5.

    Article  CAS  Google Scholar 

  16. Patorno E, Huybrechts KF, Bateman BT, Cohen JM, Desai RJ, Mogun H, Cohen LS, Hernandez-Diaz S. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med. 2017;376(23):2245–54.

    Article  CAS  Google Scholar 

  17. Zalzstein E, Koren G, Einarson T, Freedom RM. A case-control study on the association between first trimester exposure to lithium and Ebstein’s anomaly. Am J Cardiol. 1990;65:817–8.

    Article  CAS  Google Scholar 

  18. Boyle B, Garne E, Loane M, Addor MC, Arriola L, Cavero-Carbonell C, Gatt M, Lelong N, Lynch C, Nelen V, Neville AJ, O’Mahony M, Pierini A, Rissmann A, Tucker D, Zymak-Zakutnia N, Dolk H. The changing epidemiology of Ebstein’s anomaly and its relationship with maternal mental health conditions: a European registry-based study. Cardiol Young. 2017;27:677–85.

    Article  Google Scholar 

  19. Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D, Donnenfeld AE, Rieder M, Santelli R, Smythe J, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet. 1992;339(8792):530–3.

    Article  CAS  Google Scholar 

  20. Gentile S. Lithium in pregnancy: the need to treat, the duty to ensure safety. Expert Opin Drug Saf. 2012;11:425–37.

    Article  CAS  Google Scholar 

  21. Diav-Citrin O, Shechtman S, Tahover E. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry. 2014;171:785–94.

    Article  Google Scholar 

  22. Mcknight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379:721–8.

    Article  CAS  Google Scholar 

  23. Bergink V, Kushner SA. Lithium during pregnancy. Am J Psychiatry. 2014;171:712–5.

    Article  Google Scholar 

  24. Iqbal MM, Sohhan T, Mahmud SZ. The effects of lithium, valproic acid, and carbamazepine during pregnancy and lactation. J Toxicol Clin Toxicol. 2001;39:381–92.

    Article  CAS  Google Scholar 

  25. Youngs RM, Chu MS, Meloni EG, Naydenov A, Carlezon WA Jr, Konradi C. Lithium administration to preadolescent rats causes long-lasting increases in anxiety-like behavior and has molecular consequences. J Neurosci. 2006;26:6031–9.

    Article  CAS  Google Scholar 

  26. Forsberg L, Adler M, Römer Ek I, Ljungdahl M, Naver L, Gustafsson LL, Berglund G, Chotigasation A, Hammar U, Böhm B, Wide K. Maternal mood disorders and lithium exposure in utero were not associated with poor cognitive development during childhood. Acta Paediatr. 2018;107:1379. https://doi.org/10.1111/apa.14152.

    Article  CAS  PubMed  Google Scholar 

  27. Haskey C, Galbally M. Mood stabilizers in pregnancy and child developmental outcomes: a systematic review. Aust N Z J Psychiatry. 2017;51:1087–97.

    Article  Google Scholar 

  28. Wesseloo R, Wierdsma AI, van Kamp IL, Munk-Olsen T, Hoogandijk WJG, Kushner SA, Bergink V. Lithium dosing strategies during pregnancy and the postpartum period. Br J Psychiatry. 2017a;211:31–6.

    Article  Google Scholar 

  29. NICE. NICE guidelines. Antenatal and postnatal mental health: clinical management and service guidance [CG192]. London: NICE; 2014.

    Google Scholar 

  30. Viguera AC, Nonacs R, Cohen LS Tondo L, Murray A, Baldessarini RJ. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry. 2000;157:179–84.

    Article  CAS  Google Scholar 

  31. Viguera AC, Whitfield T, Baldessarini RJ Newport DJ, Stowe Z, Reminick A, Zurick A, Cohen LS. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164:1817–24.

    Article  Google Scholar 

  32. Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord. 2004;6:2–13.

    Article  CAS  Google Scholar 

  33. Bank AM, Stowe ZN, Newport DJ, Ritchie RJ, Pennell PB. Placental passage of antiepileptic drugs at delivery and neonatal outcomes. Epilepsia. 2017;58:e82–6.

    Article  CAS  Google Scholar 

  34. Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry. 2010;44:99–108.

    Article  Google Scholar 

  35. Campbell E, Kennedy F, Russell A. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2014;85:1029–34.

    Article  CAS  Google Scholar 

  36. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261:579–88.

    Article  CAS  Google Scholar 

  37. Baker GA, Bromley RL, Briggs M, Cheyne CP, Cohen MJ, García-Fiñana M, Gummery A, Kneen R, Loring DW, Mawer G, Meador KJ, Shallcross R, Clayton-Smith J, Liverpool and Manchester Neurodevelopment Group. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology. 2015;84:382–90.

    Article  CAS  Google Scholar 

  38. Van der Pol MC, Hadders-Algra M, Huisjes HJ, Touwen BC. Antiepileptic medication in pregnancy: late effects on the children’s central nervous system development. Am J Obstet Gynecol. 1991;164:121–8.

    Article  Google Scholar 

  39. Gedzelman E, Kimford J, Meador MD. Antiepileptic drugs in women with epilepsy during pregnancy. Ther Adv Drug Safe. 2012;3:71–87.

    Article  Google Scholar 

  40. Hernández-Díaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, Holmes LB, North American AED Pregnancy Registry; North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78:1692–9.

    Article  Google Scholar 

  41. Eriksson K, Viinikainen K, Mönkkönen A, Aikiä M, Nieminen P, Heinonen S, Kälviäinen R. Children exposed to valproate in utero--population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res. 2005;65:189–200.

    Article  CAS  Google Scholar 

  42. Casassus B. France bans sodium valproate use in case of pregnancy. Lancet. 2017;390(10091):217.

    Article  Google Scholar 

  43. Arkilo D, Hanna J, Dickens D. Pregnancy and neurodevelopmental outcomes with in-utero antiepileptic agent exposure. A pilot study. Eur J Paediatr Neurol. 2015;19:37–40.

    Article  Google Scholar 

  44. Kong L, Zhou T, Wang B, Gao Z, Wang C. The risks associated with the use of lamotrigine during pregnancy. Int J Psychiatry Clin Pract. 2018;22:2–5.

    Article  CAS  Google Scholar 

  45. Wesseloo R, Liu X, Clark CT, Kushner SA, Munk-Olsen T, Bergink V. Risk of postpartum episodes in women with bipolar disorder after lamotrigine or lithium use during pregnancy: a population-based cohort study. J Affect Disord. 2017b;218:394–7.

    Article  CAS  Google Scholar 

  46. Alsaad AM, Chaudhry SA, Koren G. First trimester exposure to topiramate and the risk of oral clefts in the offspring: a systematic review and meta-analysis. Reprod Toxicol. 2015;20:45–50.

    Article  Google Scholar 

  47. Hernandez-Diaz S, Huybrechts KF, Desai RJ Cohen JM, Mogun H, Pennell PB, Bateman BT, Patorno E. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology. 2018;90:e342–51.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CH Charles Perrens, Bordeaux, France

    Anne-Laure Sutter-Dallay

  2. Bordeaux Population Health Research Center, INSERM 1219, Bordeaux University, Bordeaux, France

    Anne-Laure Sutter-Dallay

  3. Pharmaco-Epidemiology and Population Health Team, Bordeaux University, Bordeaux, France

    Anne-Laure Sutter-Dallay

  4. CESP, INSERM, UMR1178, Univ Paris Sud, Le Kremlin Bicêtre, France

    Florence Gressier

  5. Department of Psychiatry, Bicêtre University Hospital, Univ Paris Sud, Le Kremlin Bicêtre, France

    Florence Gressier

Authors
  1. Anne-Laure Sutter-Dallay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Florence Gressier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne-Laure Sutter-Dallay .

Editor information

Editors and Affiliations

  1. Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey

    Faruk Uguz

  2. Psychopharmacological, Drug Misuse and Novel Psychoactive Substances Research Unit, University of Hertfordshire, Hatfield, UK

    Laura Orsolini

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sutter-Dallay, AL., Gressier, F. (2019). Mood Stabilizers in Pregnancy. In: Uguz, F., Orsolini, L. (eds) Perinatal Psychopharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-92919-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92919-4_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92918-7

  • Online ISBN: 978-3-319-92919-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation